Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study

Background. Recombinant T-cell receptor ligand 1000 (RTL1000) is a single-chain protein construct containing the outer two domains of HLA-DR2 linked to myelin-oligodendrocyte-glycoprotein- (MOG-) 35–55 peptide. Analogues of RTL1000 induce T-cell tolerance, reverse clinical and histological disease,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Yadav, Vijayshree, Bourdette, Dennis N., Bowen, James D., Lynch, Sharon G., Mattson, David, Preiningerova, Jana, Bever, Christopher T., Simon, Jack, Goldstein, Andrew, Burrows, Gregory G., Offner, Halina, Ferro, Al J., Vandenbark, Arthur A.
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi Publishing Corporation 2012
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3328144/
https://ncbi.nlm.nih.gov/pubmed/22548151
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2012/954739
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados